NCS Testing Technology (300797) Fundamentals 2026 — P/E 25.5x, Revenue Analysis | SniperIQ
NCS Testing Technology (300797) is a CN-listed Industrials company in Industrial - Machinery with a market capitalization of ¥4.2B, trading at ¥10.99 on the SHZ. This SniperIQ fundamentals page covers NCS Testing Technology's valuation (P/E 25.5x, P/B 3.2x), profitability (net margin 13.3%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is NCS Testing Technology's market cap?
NCS Testing Technology (300797) has a market capitalization of approximately ¥4.2B, trading at ¥10.99 on the SHZ. Market cap moves with the live share price.
What is NCS Testing Technology's P/E ratio?
NCS Testing Technology's trailing twelve-month P/E ratio is 25.5x, with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Industrials sector peers rather than read in isolation.
How profitable is NCS Testing Technology?
NCS Testing Technology runs a net profit margin of 13.3%, a gross margin of 48.3%, and an operating margin of 13.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does NCS Testing Technology generate?
NCS Testing Technology reported revenue of ¥1.2B for fiscal year 2025, with net income of ¥156M and earnings per share (EPS) of 0.41. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does NCS Testing Technology pay a dividend?
NCS Testing Technology offers a trailing dividend yield of about 1.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is NCS Testing Technology financially healthy?
NCS Testing Technology carries a debt-to-equity ratio of 0.09x and a current ratio of 2.11x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is NCS Testing Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For NCS Testing Technology (300797) the key facts are: market cap ¥4.2B, P/E 25.5x, revenue ¥1.2B, 52-week range 10.82-21.9. Weigh valuation, profitability, growth, and balance-sheet strength against Industrials peers and form your own view.
Track NCS Testing Technology's full fundamentals live
Get NCS Testing Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.